With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
Earnings call Legend Biotech posted 64% year-over-year revenue growth in Q4 2025, propelled by CARVYKTI’s expanding market share and manufacturing scale. Gross margin stabilized at 61%, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results